Otsuka has agreed a plan with the Global Drug Facility to improve the worldwide distribution of its novel TB drug delamanid, but several access groups are asking for additional action to combat the multidrug-resistant form of the disease.
Otsuka Pharmaceutical Co. Ltd. has entered into an agreement with the Stop TB Partnership's Global Drug Facility (GDF) to improve international access to Deltyba (delamanid), the Japanese firm's novel treatment for multidrug-resistant tuberculosis (MDR-TB).
The deal, reached through its Otsuka Novel Products subsidiary in Germany, paves the way for access to the product through...
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
